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Case Report
Introduction
Thrombotic microangiopathy (TMA) is a pathologic pattern 
of injury, characterized by systemic microthrombi, hemo-
lytic anemia, and thrombocytopenia, leading to end-organ 
ischemia affecting particularly the kidney and brain.1 The 
pathologic feature of TMA syndromes is arteriolar and capil-
lary thrombosis causing vascular damage with characteristic 
abnormalities in the endothelium and vessel wall.1,2
The new classification of TMA proposed by Dr James 
George classifies TMA under primary and secondary disorders.1 
Primary TMA is composed of 9 disorders, and the most com-
monly discussed are thrombocytopenic thrombotic purpura and 
hemolytic uremic syndrome. Secondary TMAs are related to 
malignancy, connective tissue disease, malignant hypertension, 
pregnancy, and renal or stem cell transplantation (rejection or 
drug toxicity).1 Plasma cell dyscrasias are frequently encoun-
tered malignancies often associated with kidney disease through 
the production of immunoglobulin.2 In this article, we are pres-
ent and discuss a very rare case of TMA, which was later diag-
nosed to have an underlying multiple myeloma (MM).
Case Report
A 42-year-old Haitian man with past medical history of mixed 
connective tissue disease with pulmonary hypertension on 
home oxygen and chronic diastolic heart failure with pre-
served ejection fraction presented to an outside hospital with 
shortness of breath, weight loss, fatigue, and pedal edema for 
about 14 days. He was diagnosed with rapidly progressing 
acute kidney injury (AKI) and was transferred to our tertiary 
care hospital for further management. During the hospitaliza-
tion, he was found to have a serum creatinine of 3.07 mg/dL 
and urinalysis showing 2+ proteins and 2+ blood with dys-
morphic red blood cells on microscopy. At admission hemo-
globin was 6.0 g/dL, mean corpuscular volume 87.5 fL, 
hematocrit 20.3%, white blood cell count was 5300/m3, neu-
trophils were 90.0%, and platelet count of 130 000/mm3. 
Viral serologies of hepatitis B, hepatitis C, and HIV were 
negative. Quantiferon TB Gold test for tuberculosis was neg-
ative. The serological tests for autoimmune diseases, which 
include ANA, ANCA, HLA-B27, anti-Smith antibody, 
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Abstract
Thrombotic microangiopathy (TMA) describes a pathological process of microvascular thrombosis, consumptive 
thrombocytopenia, and microangiopathic hemolytic anemia, leading to end-organ ischemia and infarction, affecting particularly 
the kidney and brain. TMA is a pathological feature of a number of clinical disorders including thrombotic thrombocytopenic 
purpura, hemolytic uremic syndrome, and atypical hemolytic uremic syndrome. Rare but important, TMA may also occur 
in malignancy, connective tissue disease, malignant hypertension, and renal transplantation (rejection or drug toxicity). We 
present a very rare case where the patient developed acute kidney injury from TMA but found to have multiple myeloma as 
the possible underlying etiology.
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anti SS-A, anti SS-B, anti-centromere B antibody, anti-Jo 
antibody, myeloperoxidase antibody, and cyclic citrullinated 
peptide, were negative except for anti-RNP and ESR. Serum 
albumin was 2.1 g/dL, and serum globulin was 4.7 g/dL.
Percutaneous renal biopsy under light microscopy showed 
some glomeruli with ischemic changes characterized by 
wrinkling glomerular capillary walls. Mild interstitial fibrosis 
and tubular atrophy was seen and a few arteries and arterioles 
showed fibrin thrombi in the vessel lumen. There was mild to 
moderate arteriosclerosis. Under direct immunofluorescence 
there was no significant glomerular staining for IgG, IgA, 
IgM, C3, and C1q, fibrinogen, albumin, and kappa and 
lambda light chains. There was nonspecific tubular cast stain-
ing for IgA and kappa and lambda light chains. There were no 
immune-type electron dense deposits in mesangial regions, 
tubular basement membranes, interstitium, peritubular capil-
laries, or capillary walls by electron microscopy; however, 
mild effacement of podocyte foot processes was seen. The 
biopsy was interpreted as suggestive of renal TMA with mild 
tubular atrophy and interstitial fibrosis (see Figure 1).
The patient remained anemic with hemoglobin of 8 g/dL 
requiring 3 red blood cell transfusions over the hospitaliza-
tion of 4 weeks. Additional laboratory results of lactate dehy-
drogenase 359 U/L, haptoglobin <8 mg/dL, and schistocytes 
in the peripheral blood smear suggested hemolysis. A platelet 
count of 74 000/mm3 with normal megakaryocytes in the 
bone marrow done later suggested consumptive thrombocy-
topenia. With the evidence of ongoing hemolysis, thrombo-
cytopenia, and renal failure, a diagnosis of TMA was made 
and the patient was started on plasma exchange of 1.5 plasma 
volumes daily for 5 days. Despite the treatment renal func-
tion worsened and hemodialysis was initiated.
After 25 days in hospital, urine volume increased and cre-
atinine stabilized around 2.0 mg/dL. Workup of TMA prior 
to plasma exchange showed normal complement levels with 
C3 level of 119.0 mg/dL, complement C4 level of 36.70 mg/
dL, and ADAMTS 13 activity level of 57%. Serum protein 
electrophoresis showed albumin 32.66% of a total protein 
6.40 g/dL and M-spike 30.05%. Serum immunofixation 
identified the M-spike as IgG at a level of 2199 mg/dL. 
Figure 1. Kidney biopsy. (A) Electron microscopy. No immune-type electron dense deposits in mesangial or capillaries walls. There is 
mild effacement of podocyte foot processes. (B) Jones; mesangiolysis. (C) Jones; interstitial edema. (D) Direct immunofluorescence. No 
significant glomerular and tubular staining. (E) Trichrome; focal interstitial fibrosis. (F) Light microscopy. Jones; fibrin thrombus in artery 
and ischemic glomeruli.
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Serum kappa free light chain was 18.2 mg/dL, lambda free 
light chain was 5.28 mg/dL, and an elevated kappa/lambda 
ratio of 3.45. Urine protein was 1994 mg/g of creatinine, 
which was 15.1% globulin and 3.7% monoclonal by electro-
phoresis. A bone marrow biopsy showed clonal plasmacyto-
sis consistent with plasma cell dyscrasia with 18% plasma 
cells. Unfortunately, the patient developed severe sepsis and 
died before initiation of management for MM.
Discussion
MM accounts for 1% of neoplastic disease and 13% of 
hematological malignancies. Renal impairment occurs in 
20% to 40% of patients with MM and more than 80% have 
proteinuria.3 The mechanisms of kidney injury can be 
grouped into immunoglobulin-dependent and immunoglob-
ulin-independent categories. The 3 most common forms of 
monoclonal immunoglobulin-mediated kidney disease are 
cast nephropathy, monoclonal immunoglobulin deposition 
disease, and AL amyloidosis. The other rare causes of kid-
ney injury in MM are glomerulonephritis, tubulointerstitial 
nephritis, minimal change disease, IgA nephropathy, and 
hyperviscosity syndrome.4 Myelomas that produce only 
light chains are responsible for 40% to 60% of severe 
myeloma-associated kidney injuries, reflecting the nephro-
toxicity of the filtered light chains.4
Our case was unique as TMA was the initial presentation, 
which is very rare for kidney injury induced by MM. In this 
case kidney failure developed acutely and required renal 
replacement therapy. Laboratory workup was consistent with 
microangiopathic hemolysis with normal ADAMTS13 activ-
ity level and normal complement levels. Kidney biopsy 
showed no immune deposit but there were microthrombi in a 
few arteries and arterioles. Serum and urine electrophoresis, 
serum immunofixation, and bone marrow biopsy result con-
firmed the diagnosis of MM. The patient developed sepsis 
and died before definitive treatment for MM was started.
Various mechanisms of TMA in MM have been 
proposed.4 TMA in MM patients can result from either direct 
Ig-induced endothelial injury, or IgG antibody against 
ADAMTS13 leading to thrombocytopenic thrombotic pur-
pura. The pathogenesis of Ig-induced endothelial injury 
involves the light chains that are filtered through the glom-
erulus. They undergo chemical degradation and induce pro-
inflammatory cytokines, such as IL-6 and IL-8. These light 
chains lead to formation of redox-sensitive transcription fac-
tor NF-κB and mitogen-activated protein kinase, which in 
turn results in inflammatory cell infiltration, matrix deposi-
tion, and fibrosis.5
Other suggested mechanisms of TMA are that sys-
temic chemotherapy or stem cell transplantation damage 
endothelium.6 There is one case report of the successful 
use of eculizumab in a patient with MM and TMA sug-
gesting a complement-mediated mechanism that has not 
been investigated.7
In one autopsy series of 77 MM patients there were 10 
cases of TMA, some after allogenic hematopoietic stem cell 
transplant.6 Another article reported 9 cases of TMA with 
MM. Of these, 4 patients had TMA as the initial presentation 
of MM, and 5 patients were on treatment, most often bort-
ezomib-based regimens. Another study demonstrates that 
TMAs can occur in MM outside of the context of allogenic 
hematopoietic stem cell transplant. In roughly one third of 
patients, TMAs were the initial presentation of MM and 
improved with treatment.8 There are reported cases suggest-
ing that an acquired von Willebrand factor disease might 
develop during the course of MM.7,9-11 In these patients, the 
suggested mechanism is the prevention of the interaction of 
GP1b with von Willebrand factor due to the paraproteins.7,9-12 
Another study reported renal function improvement after 
administration of a monoclonal antibody against C5 (eculi-
zumab) in a post–bone marrow transplant MM patient.13 This 
leads to the hypothesis that complement or complement-
mediated factors can also be one of the causative factors of 
renal damage in MM patients. Little data are available to 
support this statement.
Signs and symptoms of myeloma and plasma cell dys-
crasias are nonspecific and include weight loss, malaise, 
fatigue, bone pain, anemia, and thrombocytopenia. 
Similarly, the symptoms of the kidney injury are also non-
specific, and occasionally the patient will present with a 
fulminant syndrome of dialysis-dependent AKI; thus, pri-
mary care physicians, nephrologists, and hematologists/
oncologists should consider plasma cell dyscrasias in the 
differential diagnosis of AKI and hematological abnormali-
ties including TMA.
The deadly consequences of TMA in MM as seen in our 
patient warrant further studies to be done in order to learn 
more about the pathophysiology including possible role of 
ADAMTS13, complement, and complement-mediated fac-
tors. Further studies are also required to define the potential 
benefit of treatment with plasmapheresis for TMA in MM.
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